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Abstract: Hsp90 chaperone has been identified as an attractive pharmacological target to combat cancer. However, some metastatic 
tumors either fail to respond to Hsp90 inhibition or show recovery necessitating irreversible therapeutic strategies. In response to this 
enforced senescence has been proposed as an alternate strategy. Here, we demonstrate that inhibiting Hsp90 with 17AAG sensitizes 
human neuroblastoma to DNA damage response mediated cellular senescence. Among individual and combination drug treatments, 
17AAG pre-treatment followed by doxorubicin treatment exhibited senescence-like characteristics such as increased nucleus to cyto-
plasm ratio, cell cycle arrest, SA-β-gal staining and the perpetual increase in SAHF. Doxorubicin induced senescence signaling was 
mediated by p53-p21CIP/WAF-1 and was accelerated in the absence of functional Hsp90. Sustained p16INK4a and H3K4me3 expressions 
correlating with unaffected telomerase activation annulled replicative senescence and appraised stress induced senescence. Despite 
increases in [(ROS)i] and [(Ca2+)i], a concomitant increase in cellular antioxidant defense system suggested oxidation independent 
senescence activation. Sustained activation of survival (Akt) and proliferative (ERK1/2) kinases fosters robustness of cells. Invigorat-
ing senescent cells with growth factor or snooping with mTOR or PI3 kinase inhibitors compromised cell survival but not senescence. 
Intriguingly, senescence-associated secretory factors from the senescence cells manifested established senescence in neuroblastoma, 
which offers clinical advantage to our approach. Our study discusses tumor selective functions of Hsp90 and discusses irrefutable strate-
gies of Hsp90 inhibition in anticancer treatments.
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Introduction
Heat shock proteins (Hsps) are implicated in evading 
stress induced cell death programming and in adap-
tive cellular responses to stress.1 The Hsp90 chaper-
one functions are entangled with tumor progression 
identifying this protein as a cancer chaperone.2 In 
support of this, the surface expression of Hsp90 in 
cancers of the human nervous system (NB69, SH-
SY5Y, SK-N-SH) correlated with enhanced survival 
and proliferation, whose functional blockade with 17- 
allylamino-17-demethoxygeldanamycin (17AAG) 
or geldanamycin compromised cell survival.3–5 As an 
exception, the drug resistant and metastatic human 
neuroblastoma, IMR-32 failed to respond to 17AAG 
treatment6 despite Hsp90 being the central regula-
tor of cell signaling.7,8 The non-responsiveness may 
relate to major regulatory mechanisms such as tumor 
suppression.
In addition to essential oncogenic kinase activa-
tion, inactivation of tumor suppressor mechanisms 
involving p53-p21CIP/WAF-1 and pRb-p16INK4a are sig-
nificantly implicated in cancer progression. Despite 
occurrence of mutations in p53 tumor suppressor 
gene in a large number of human tumors, neuroblas-
toma retains functional protein, and this could be the 
reason why inactivating mutations in p53 enhances 
chemotherapy induced cytotoxicity.9 The neuroblas-
toma also comprise constitutive p16INK4a expression 
independent of Rb phosphorylation.10 The constitu-
tive p16INK4a expression was presumed to act against 
not only cytotoxic pathways but to bypass senescence 
programming. To circumvent chemotherapeutics 
induced non-selective cytotoxicity and to promote 
the therapeutic potential of pharmacological inhibi-
tors of Hsp90 in metastatic tumors, several combina-
tion drug treatment strategies have been proposed.6–8 
These combination treatments, however, suffer due to 
induced stress response mechanism, which may help 
in cell recovery and in making aggressive cancer phe-
notypes or affect bystander cells due to lack of tumor 
selectivity.
The DNA topoisomerase I inhibitor, doxorubicin 
has been shown to induce senescence-like phenotype 
in cells exposed to prolonged treatments. Subsequent 
to these findings, doxorubicin combination with Akt 
targeting was shown to be effective in Akt positive 
cells for cancer treatment.11 Nevertheless, neuroblas-
toma cells possess altered PI3K-Akt-mTOR  pathway 
activation that correlates with poor prognosis12 and do 
not respond to Akt destabilization even with 17AAG 
induced disassociation of Akt from Hsp90 binding.6 
Considering the constraints associated with 17AAG 
response in IMR-32 neuroblastoma, we hypoth-
esized that functional bereavement of Hsp90 status 
combining with doxorubicin may effectively combat 
cancer.
In the present study, we investigated the acceler-
ation of pre-sensitizing effects of Hsp90 inhibition 
on doxorubicin induced cellular senescence. The 
acquired senescence phenotype was characterized 
by increased senescence associated β-galactosidase 
(SA-β-gal) activity and senescence associated het-
erochromatin foci (SAHF). Senescence obtained 
was neither associated with oxidative damage 
nor involving telomere shortening.  Biochemical 
 analyses suggested involvement of p53-p21CIP/WAF-1 
 pathways in senescence activation, which is inde-
pendent of pRb-p16INK4a pathway. Further, the senes-
cence phenotype was resistant to growth stimulus 
and exhibited multidrug resistance. The secretory 
factors present in the conditioned medium can acti-
vate senescence-like phenotype in other human 
tumor cells. Our findings suggest that Hsp90 acts 
as a barrier to enforced senescence response in 
tumor cells.
Materials and Methods
cell cultures, treatments and reagents
IMR-32, SRA01, and jurkat cells were from  American 
Type Cell Culture. Cells were grown and maintained 
in DMEM containing 10% fetal bovine serum albu-
min in the presence of penicillin (100 U/mL), strep-
tomycin (50 µg/mL) and kanamycin (30 µg/mL) at 
37 °C in a humidified incubator with 5% CO
2
 supply. 
For treatments, 2 × 105 cells were grown on cover 
glass (22 × 22 mm, Fisher Scientific, USA) in a 
6-well culture dish (nunc, Thermo Scientific, USA) 
and incubated in complete medium either with doxo-
rubicin (Sigma-Aldrich, USA) or with 17AAG (Invi-
vogen, USA) at different time intervals. The effective 
drug concentrations were standardized by analyzing 
their ability to induce cytotoxicity in case of doxoru-
bicin and to degrade 90% of Hsp90 client proteins in 
case of 17AAG. The concentration used throughout 
the manuscript for doxorubicin was 0.1 µM and for 
17AAG it was 2 µM.
hsp90 inhibition accelerates senescence
Drug Target Insights 2012:6 21
cell based assays
Fluorescence activated cell sorting (FACS, FACSCal-
ibur, Becton Dickinson, USA) analysis for DNA con-
tent was performed by staining cells with propidium 
iodide (50 µg/mL; Sigma-Aldrich, USA). To measure 
intracellular reactive oxygen species, [(ROS)i], cells 
were stained with CM-H
2
DCFDA (5 µM; Dojindo, 
Japan), to measure intracellular calcium, [(Ca2+)i], 
cells were stained with Fluo 3-AM (1 µM; Dojindo, 
Japan), to measure a change in mitochondrial mem-
brane potential (∆Ψm), cells were stained with JC1 
(40 nM; Invitrogen, USA). After incubation for 
20 min in the dark, cells were washed off the fluoro-
phore three times with PBS and analyzed in MoFlow 
( Becton Dickinson, USA). Each experiment was 
repeated a minimum of three for reproducibility and 
statistical significance. The data were analyzed with 
BD Cell-Quest Pro v5.2 software.
Senescence associated β-galactosidase 
(SA-β-gal) staining
The phase-contrast images of cells were captured 
using Axiovert 200 microscope (20× magnification; 
Carl Zeiss, Germany). The SA-β-gal staining was 
performed as explained earlier13 and observed under 
the Axiovert 200 microscope (20× magnification).
reverse Transcriptase Polymerase 
chain reaction (rT-Pcr) 
The RNA was isolated using TRIZOL (Sigma-Aldrich, 
USA) method. The first strand cDNA was prepared from 
1 μg total RNA using Prime Script 1st strand cDNA 
synthesis kit (Takara Bio Inc., Japan). The gene specific 
cDNA amplifications were performed using qualita-
tive PCR primers in a dual block PCR machine (DNA 
Engine; Bio-Rad, USA). The primers used were cell 
cycle regulators: p21 (Accession no. NM_000389.3), 
sense, 5′-GGAGCTGGGCGC GGATTC-3′, anti-
sense, 5′-AGGCCCTCGCGC TTCCAG- 3′; p53 
(Accession no. NM_000546.4), sense, 5′-TTGCGT-
TCGGGCTGGGAG-3′, antisense, 5′-GCCGCCGGT-
GTAGGAGCT-3′; p16 (Accession no. NM_000077.4), 
sense, 5′-ATTGAATTCATG GAGCCGGCGGCG-3′, 
antisense, 5′- ATTGGA TCCATCGGGGATGTCT-
GAG-3′; Hsps: hsp70 (Accession no. NM_005346.4), 
sense, 5′-CCA TGGTGCTGACCAAGATGAAG-3′, 
antisense, 5′-TCGTCGATCGTCAGGATGGACAC-3′; 
hsp27 (Accession no. NM_001540.3), sense, 
5′-TCCCTGGATGTCAACCACTTCG-3′, antisense, 
5′-GGGACAGGGAGGAGGAAACTTG-3′; hsp90 
(Accession no. NM_001017963.2), 5′-TCCGGTAT-
GAAAGCT TGACAG-3′, antisense, 5′-CTGGTC-
CAGATGGGCTTTGTT-3′; GAPDH, (Accession no. 
NM_002046.3), 5′-TGA AGGTCGGTGTGAACG-
GATTTG-3′, antisense, 5′-TGATGGCATGGACTGT-
GGTCATGA-3′. Quantification of blots was performed 
using Image J software. 
Immunoblot  analyses 
Cell lysates were prepared using HEPES lysis buffer 
(20 mM HEPES, 10 mM NaCl, 1.5 mM MgCl
2
, 0.1% 
Triton X-100, pH 7.6), 20 μg total protein was run on 
10% SDS-PAGE and was transferred on to nitrocellu-
lose membrane. The primary antibodies, HRPO- and 
FITC-conjugated secondary antibodies were obtained 
from Santa Cruz Biotechnology Inc., (USA). 
Laser Scanning confocal Imaging 
Microscopy 
Staining for mitochondria and actin was performed 
in cells with CMX-Ros (200 nM; Invitrogen, USA) 
and oregon green phalloidin (50 nM; Invitrogen, 
USA) respectively and nucleus was stained with 
DAPI (50 nM; VECTASHIELD, Vector Labs, USA) 
and observed under laser scanning confocal imaging 
microscope (Leica TCS SP5, Leica Microsystems, 
Germany). All immunoflourescence experiments 
were performed on cells grown on cover glasses, with 
p16, trimethyl histone (H3K4me3) and γH2AX anti-
bodies (Santa Cruz Biotechnology Inc., USA).
Rhodamine 123 (Rh123) efflux assay
Cells were incubated with Rh123 (1 µM; Dojindo, 
Japan) and analyzed in the FACSCalibur. The Rh123 
efflux ratio was calculated by dividing the mean chan-
nel number with cyclosporin A (CsA) and mean chan-
nel number with Rh123 alone.
real-time polymerase chain reaction 
(real-time Pcr)
The telomerase activity was measured by  quantitative 
telomerase detection kit (US Biomax, USA). 
A standard real time PCR was run in Realplex Real-
time PCR machine (Eppendorf Mastercycler ep 
gradient S, Germany) with the TSR oligonucleotide 
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and the telomerase activity was calculated from the 
standard curve.
colony forming assay (cFA)
Cells were mixed with molten soft agar at 37 °C, 
poured over a base layer of agar and allowed to grow 
in complete medium with 5% CO
2
 supply. After eight 
days, cells were stained with 0.1% crystal violet and 
observed under Axiovert 200 microscope in dif-
ferential interference contrast microscope (DIC, 5× 
magnification). The colony size in micro meters was 
calculated from πr2 and plotted.
neo-vascularization assay
Cover glasses were pre-coated with matrigel (BD 
Biosciences, USA) for 45 min and cells were spread 
on matrigel, incubated with complete medium con-
taining the drugs for 24 h and the tube or colony for-
mation was observed under Axiovert 200 microscope 
in DIC (5× magnification).
sirnA knockdown of hsp90
Hsp90 siRNA was designed using Invitrogen 
BLOCK-iT™ RNAi designer software from HSP90 
cDNA (Accession No. NM_005348.2). The three siRNA 
used in the present study were, oligo1, 5′-GAA CAAA 
CAAGATCGAACTCT-3′; oligo2, 5′-GAGA GAGCT 
CATTTCAAATTCATCA-3′; oligo3, 5′-ACTCTGG 
GAAAGAGCTGCATATTAA-3′. The siRNA was 
introduced into the cells using nanoparticle based 
X-fect transfection reagent (Clontech, USA).
evaluation of conditioned medium (cM) 
for senescence promoting secretory 
factors (SASPs)
IMR-32 cells were 17AAG pre-treated for 24 h fol-
lowed by doxorubicin for 5 days, and after confirm-
ing the SA-β-gal positive staining of cells, the CM 
was collected and used for subsequent experiments. 
The immortalized human lens epithelium (HLE) 
cells- SRA01 and human T-lymphocytes- jurkat 
(0.1 × 106/mL) grown on cover glasses (18 × 18 mm, 
Fisher Scientific, USA) were replaced with CM and 
maintained at standard culture conditions. The cells 
were monitored every day under the microscope for 
typical senescence morphology. Cells that exhib-
ited senescence like-phenotype were stained for 
β-galactosidase and observed under the microscope.
Statistical analyses
The data presented are mean ± SEM of minimum three 
independent experiments. The significance was calcu-
lated by student’s t-test (SigmaPlot 10.0) and a value 
minimum of P , 0.05 is considered significant.
Results
17AAg combination decreases 
doxorubicin induced senescence 
response
Senescent cell morphology is typically associated 
with increased nucleus to cytoplasm ratio with pro-
tracted cellular extensions and increased SA-β-gal 
staining.14 At first, various concentrations of drugs 
(17AAG- 0.5 µM to 10 µM or doxorubicin-0.1 µM to 
2.0 µM) was examined for induced cytotoxicity. The 
optimum concentrations (0.1 µM for doxorubicin and 
2.0 µM for 17AAG) were selected where we observed 
90% client protein degradation for Hsp90 and mini-
mal DNA damage response using  doxorubicin. 
To determine whether SA-β-gal positive cells are 
induced by doxorubicin (0.1 µM), 17AAG (2.0 µM) 
or their combination treatment, cells were treated 
for 6-days, stained with X-gal and observed under 
the  microscope. Doxorubicin treatment precisely 
increased SA-β-gal positive cells with extended cell 
morphology (35% ± 5%, P , 0.001). The 17AAG 
treatment showed aspecific β-gal staining, which 
did not correlate with senescence  morphology. 
 Doxorubicin and 17AAG combination treatment 
decreased SA- β-gal positive cells (14% ± 3% against 
35% ± 5% of doxorubicin), thus, suggested impaired 
senescence response on prolonged Hsp90 inhibition 
(Fig. 1A and 1A1, P , 0.01).
To understand the indistinctness in β-gal staining of 
cells between doxorubicin and 17AAG treatments, live 
cell morphology was examined under the  microscope. 
Doxorubicin treatment resulted in extended cellular 
connections along with increased nucleus to cyto-
plasm ratio, however, 17AAG treatment showed loss 
of surface contact. In the combination treatment, a 
few cells were found still attached to the substratum 
even on 6-day long treatment (Suppl. Fig. 1A). The 
adherent cells thus can be related to only SA-β-gal 
positive cells. The differential senescence response to 
different drugs may be related to survival potential of 
cells on prolonged treatments. Investigating the DNA 
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 content of cells during the treatments by FACS anal-
ysis uncovered that doxorubicin and 17AAG treat-
ments gradually increased subG1 population of cells. 
 Interestingly, the combination treatment showed pre-
cipitous 50% increase (P , 0.001) in subG1 cells as 
early as in 3-days (Suppl. Fig. 1B).
17AAg and its combination  
with doxorubicin induces stress response
Tumor suppressors play a major role in deciding the 
fate of cells under stress conditions. To investigate their 
functional role in senescence, the expression levels of 
p21CIP/WAF-1, p16INK4a and p53 were examined by RT-PCR 
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Figure 1. Effect of doxorubicin, 17AAG and their combination treatments on IMR-32 neuroblastoma cells. (A) SA-β-gal staining of control and 6-day drug 
treated cells. The images were captured at 20x magnification (Axiovert 200, Carl Zeiss). (A1) Statistical representation of individual and combination drug 
treatments induced percent SA-β-gal positive cells. (B) rT-Pcr analysis of cell cycle regulators and heat shock genes on the onset of stress induced 
cellular senescence. (B1 and B2) Gene expression data was used to calculate the expression ratios in reference to GAPDH. (c) Immunoblot analysis of 
proteins from cell cycle, hsps and signal transduction.
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analyses at 2-, 4- and 6-day post-treatments. The indi-
vidual treatments showed a gradual decrease in p21CIP/
WAF-1 along with the time of treatment. The combination 
treatment though showed an initial decrease in 2-day 
treatment, and a significant increase was observed by a 
6-day treatment. Correlating with p21CIP/WAF-1 there was 
an increase in p53 expression in 17AAG (up to 4-day) 
and its combination with doxorubicin (by 1-day) cor-
responding to activation of cellular stress response. The 
doxorubicin induced p53, however, may be related to 
DNA damage response. Additionally, increased expres-
sion of stress proteins, Hsp27, Hsp70 and Hsp90 upon 
17AAG and its combination with doxorubicin treatments 
further confirm activation of stress response (Fig. 1B). 
The ratio between each target gene and GAPDH expres-
sion was calculated using ‘Image J’ analysis to normal-
ize loading controls and represented in bar diagram. 
 Therefore the bar diagrams represent fold gene expres-
sion compared to GAPDH (Fig. 1B1 and Fig. 1B2).
To study protein levels of tumor suppressors, signal 
transduction and stress proteins, cell lysates collected 
at day 2, 4 and 6 of the treatments were examined 
by immunoblot analysis. Prolonged treatment of cells 
with individual drugs displayed gradual but radical 
decrease in cyclin dependent kinases, cdk1, cdk2 and 
cdk6, which has implications both in G1/S and G2/M 
cell cycle transitions. Prolonged combination treat-
ment displayed a decrease in cdk6 alone that is involved 
in the G0 to G1 cell cycle  transition.  Doxorubicin 
and 17AAG treatments showed decrease in Hsp27, 
Hsp70 and Hsp90 levels; interestingly, only Hsp90 
levels were unaffected by the combination treatment. 
Consistent with Hsp90 levels, Akt and ERK1/2 basal 
levels were not affected by the combination treatment 
compared to individual treatments. However, the 
phosphorylation status of Akt and ERK1/2 was found 
to be decreased (Fig. 1C).
17AAg pre-treatment but not the 
combination treatment accelerates 
senescence response
We excluded the combination treatments in our sub-
sequent study, because prolonged treatments inter-
fered with senescence activation by inducing early 
cytotoxicity (Suppl. Fig. 1B). In the following experi-
ments, we studied pre-sensitizing effects of drugs on 
senescence acceleration. In brief, cells were treated 
with doxorubicin or 17AAG for 24 h and the drug 
 containing medium was replaced with fresh medium 
containing 17AAG or doxorubicin for 5-days were 
examined for SA-β-gal staining.  Doxorubicin pre-
treatment followed by 17AAG treatment showed 
fewer SA-β-gal positive cells (15% ± 2%) by day-6 
and 17AAG pre-treatment followed by doxorubicin 
treatment resulted in early (day-2, data not shown) 
SA-β-gal positive cells (65% ± 11%) by day-6 
(Fig. 2A and 2 A1, P , 0.001). These results suggested 
that 17AAG pre-treatment accelerates doxorubicin 
induced cellular senescence, whereas, doxororubicin 
pre-treatment showed a response similar to doxoru-
bicin treatment (compare Fig. 1A with Fig. 2A). In 
both the pre- treatments, SA-β-gal activity was cor-
relating with typical senescence morphology (Suppl. 
Fig. 2A). However, doxorubicin pre- treatment 
resulted in enhanced cytotoxicity in comparison 
with 17AAG pre-treatment (Suppl. Fig. 2B). These 
findings establish that prolonged treatment of cells 
with 17AAG affects senescence activation. Further, 
a decrease in cytotoxicity (Fig. 2B, P , 0.001) in 
17AAG pre-treatment was correlated with enhanced 
senescence (Fig. 2A), which is in agreement with the 
accumulation of cells in G1/S being a pre-requisite 
for senescence activation (14; Fig. 2C, P , 0.001).
17AAg pre-treatment retains survival 
potential
To investigate the difference in molecular mecha-
nism of senescence activation in the pre-treatments, 
the  RT-PCR analysis of cell cycle regulators was 
 performed. A gradual decrease in p21CIP/WAF-1 in doxo-
rubicin pre-treatment and a steady increase in 17AAG 
pre-treatment correlated with increased expression 
of p53 suggesting involvement of p53 and p21CIP/
WAF-1 in senescence activation. The increased p21CIP/
WAF-1 but not p16INK4a expression correlated with 
enhanced SA-β-gal staining further suggested activa-
tion of stress induced cellular senescence. Increases 
in Hsp27, Hsp70 and Hsp90 levels in both the pre-
treatments suggest induced synthesis or enhanced 
stabilization of their Hsp mRNA (Fig. 2D). Specific 
gene expression was calculated using Image J analy-
sis in comparison with GAPDH to normalize loading 
controls and represented in bar diagram (Fig. 2D1).
Next, we examined protein profiles of regulatory 
molecules by immunoblot analysis using lysates of 
drug treated cells at days 2, 4 and 6. Though there 
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was some fluctuation in cdk1 levels, no signifi-
cant change was observed both in doxorubicin pre-
treatment or 17AAG pre-treatments suggesting no 
effect on mitosis. Increased cdk2 in doxorubicin 
pre- treatment suggested G1 clearing of cells but 
 variability in 17AAG pre-treatment suggest crisis in 
cellular decision making. The decrease in cdk6 levels 
in both the pre-treatments suggests inability of cells 
to re-enter cell cycle and can be argued with irre-
versible effects of cell cycle inhibition. While Hsp90 
levels were unaffected by neither of pre-treatments, 
Hsp27 and Hsp70 levels showed an initial increase 
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Figure 2. effect of pre-treatments on IMr-32 neuroblastoma cells. (A) SA-β-gal staining of control and 6-day drug treated cells. (A1) Statistical 
representation of drug pre-treatment accelerated percent SA-β-gal positive cells. The images captured at 20x magnification (Axiovert 200, Carl 
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in a 2-day treatment but its normalization by 6-day 
treatment. Correlating with increased levels of p53 
and p21CIP/WAF-1, a decrease in cyclin D1 levels sug-
gested decreased proliferation potential. In contrast 
to individual and combination treatments, in the pr-
treatments, a chronic activation of Akt and ERK1/2 
kinases suggested maintenance of survival potential 
(Fig. 2E). Considering the accelerated senescence 
with 17AAG pre-treatment with reduced cytotoxic-
ity, the subsequent experiments were performed with 
17AAG pre-treatments.
17AAg pre-treatment shows typical 
features of senescence
Actin reorganization and nuclear accumulation 
was proposed as an additional marker for cellular 
 senescence.15 To understand cellular actin dynam-
ics, actin organization was examined in 17AAG 
pretreated senescent cells with Oregon Green Phal-
loidin.  Compared to untreated cells, senescent cells 
showed a time dependent increase in peripheral actin 
bundling and accumulation of non-polymerized actin 
in the nucleus. Since sustained mitochondrial func-
tions promote senescence activation,16 mitochondria 
organization was also examined with mitotracker red 
(CMX-Ros). Decreased actin bundling further cor-
relating with increased mitochondria suggested con-
ventional senescence activation (Fig. 3A). Increased 
intracellular granularity is considered as another char-
acteristic feature of senescent cells,17 cells were ana-
lyzed for forward scatter (FSC) vs. side scatter (SSC) 
by FACS. We did not observe any change in FSC that 
provide information on particle size but observed a 
gradual increase in SSC that indicate increased intra-
cellular granularity (Fig. 3B).
Accumulation of cells in G1 though suggested rep-
licative senescence, involvement of p53- p21CIP/WAF-1 
pathway highlighted stress induced senescence. To 
further distinguish the mode of senescence on 17AAG 
pre-treatment, telomerase activity was measured from 
senescent cells. A small increase in telomerase activ-
ity and its stabilization after 2-day treatment suggested 
cellular attempt to bypass senescence reprogramming 
(Fig. 3C), which is a characteristic feature of cancer 
cells.18 While H3K4me3 marks transcription start sites of 
active genes,19 senescence associated  heterochromatin 
foci (SAHF) marks DNA damage response (DDR) to 
senescence.20 The cytoimmunofluorescence analyses 
of γH
2
AX (for SAHF) and H3K4me3 showed a grad-
ual increase in SAHF but cytosolic accumulation of 
H3K4me3 (Fig. 3D and E respectively). Telomerase 
activity is linked to p16INK4a,21 however, neuroblastoma 
exhibit chronic p16INK4a expression (Fig. 1B), which is 
thought to bypass senescence programming.22 To exam-
ine p16INK4a cellular distribution, we performed cytoim-
munoflourescence. Although, there was an increase in 
nuclear distribution in 2-day treatment, which has sig-
nificantly decreased in 4- and 6-day treatments invali-
dating its role in senescence activation (Fig. 3F).
17AAg pre-treatment induced [(rOS)i] 
and [(ca2+)i] promotes senescence  
and autophagy
Calcium permeation across membranes and mobi-
lization from organelles was associated with senes-
cence23 along with increased [(ROS)i].24 We measured 
[(Ca2+)i] and [(ROS)i] levels by FACS. In compari-
son with the control, we observed an initial increase 
in [(Ca2+)i] levels by 24.7 folds in 2-day treatment, 
which was decreased by 17.3 folds and 18.1 folds 
by day-4 and day-6 treatments (Fig. 4A, P , 0.001). 
There was also a gradual increase in [(ROS)i] levels 
by 2.6, 16.8 and 42.7 folds for day-2, -4 and -6 respec-
tively (Fig. 4B, P , 0.05). Mitochondria being the 
major source of [(ROS)i] and the ∆Ψm is considered 
to be a biomarker for oxidative stress,25 the ∆Ψm was 
measured by FACS. A gradual increase in negative 
polarization of mitochondria observed until 4-day 
time interval though suggested oxidative damage; a 
decrease by 6-day treatment suggests recovery from 
the oxidative stress (Fig. 4C, P , 0.05).
Since oxidative stress is caused by the imbalance 
between [(ROS)i] and impairment of antioxidative 
enzyme system,26 we examined the status of antioxi-
dative enzymes, superoxide dismutases, SOD1 (CuZn 
SOD, cytoplasmic), SOD2 (MnSOD, mitochondrial) 
and catalase (peroxisomes) in both doxorubicin and 
17AAG pre-treatments by immunoblot analysis. 
The induced levels of SOD1, SOD2 and decreased 
levels of catalase on both the pre-treatments sug-
gested activation of intracellular antioxidative 
defense, which also advocates non-lethal level pro-
duction of [(ROS)i] (Fig. 4D). The gene  expression 
 analyzed by Image J and represented as gene 
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versus GAPDH ratio (Fig. 4D1). In agreement with 
moderate increases in oxidative stress that correlated 
to sensitizing effects of cellular senescence27 but not 
to apoptosis, we also observed a moderate increase in 
[(ROS)i]. Since senescent cells are usually resistant 
to apoptosis or necrosis, removal of damaged cells 
could occur by autophagy (type II programmed cell 
death).  Accordingly,  senescent cells showed enhanced 
acridine orange staining, a characteristic feature of 
macroautophagy14 (Fig. 4E).
17AAg pre-treatment induced 
senescence is irreversible
Pharmacological modulator curcumin was shown to 
promote proliferation in neuroblastoma,6  therefore, 
we examined the effect of curcumin on  reversal 
hsp90 inhibition accelerates senescence
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of  senescence. Although curcumin (15 µM, 24 h) 
increased the number of SA-β-gal positive cells 
in a day-3 treatment (.133%, P , 0.05), which 
is significantly decreased by day-5 treatment 
(,37%, P , 0.05). These data (Fig. 5A) sug-
gests that  senescent cells did not respond to pro-
liferation  stimulus. We further examined the 
proliferation stimulus using epidermal growth fac-
tor (EGF, 50 nM) on senescent cells. EGF treatment 
increased subG1 cells by decreasing both G1/S and 
G2/M populations suggesting enhanced cytotoxicity 
(Fig. 5B).
The mTOR, a serine/threonine kinase activation 
favors senescence in tumor cells.28 To investigate the 
involvement of mTOR signaling in senescence, cells 
were treated with mTOR inhibitor, rapamycin for 48 h 
and compared with rapamycin (200 nM) combined 
17AAG pre-treatments at day 2, 4, and 6 using FACS. 
While rapamycin had no effect on control cells, its 
treatment to senescence directed cells resulted in 
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a decrease to G1 and increase to subG1 population 
suggesting that compromised mTOR functions com-
promises cell survival (Fig. 5C, P , 0.001). In addi-
tion to mTOR, PI3 serine/threonine kinase (PI3K) 
has been implicated in senescence.28 Therefore, we 
looked for the effect of PI3K inhibitor, wortmanin 
(200 nM) on senescent cells by using FACS. Wortma-
nin treatment also resulted in increased cell death sug-
gesting its role in senescence cell survival (Fig. 5D, 
P , 0.001).
Enhanced multidrug resistance (MDR) is one 
of the characteristic features of senescent cells.29 
To understand whether senescent cells show 
any enhanced drug resistance, we examined for 
Rh123 efflux of cells from day 3, 4 and 5 of the 
 treatment. Since curcumin interferes with MDR 
functions, curcumin was used (2 h pre-treatment 
prior to Rh123 efflux assay) to inhibit MDR func-
tions. Compared to control efflux ratio, which was 
due to constitutive MDR activation in IMR-32 (9), 
3-day  treatments showed increased efflux ratio by 
0.5 folds, suggesting enhanced functions of MDR 
on the onset of  senescence. Further, curcumin was 
effective in decreasing MDR functions as observed 
by Rh123 efflux (Fig. 5E). Concurrently, decreased 
MDR1 expression by 4-days and its re-expression 
by 6-days were observed. The chronic expressions 
of multidrug related proteins, MRP1 and MRP2 
were however, not affected by senescence activa-
tion (Fig. 5F). The representative Image J analysis 
of gene expression versus GAPDH was shown in 
bar diagram.
Senescent cells show compromised 
colony forming ability  
and neo-vascularization
It was reported that only a subset of cancer cells 
respond to drug induced cellular senescence and 
remaining cells retain metastatic potential and lead 
to recurrence.30,31 To exclude the possibility of tumor 
relapse in our senescence model, first we examined 
anchorage-independent cell growth using soft agar 
colony formation assay. Cells from post 17AAG 
pre-treatments at day 2, 4 and 6 were placed on aga-
rose coated surface and the proliferation potential of 
cells was monitored for colony forming ability. Cells 
collected on the onset of senescence showed ±65% 
decrease in colony size (Fig. 6A and 6A1). Next, 
we examined for neo- vascularization after growing 
cells on matrigel coated surface. A 6-day growth of 
control cells on matrigel resulted in  organized large 
colonies. However, cells from the onset of senes-
cence showed a significant decrease in the orga-
nized colony structures (Fig. 6B). These findings 
are consistent with SA-β-gal data that a majority of 
cells enter senescence state, which acts as an anti-
proliferative and anti-metastatic  mechanism. Cells 
that fail to enter senescence state were found to be 
eliminated by cytotoxicity (compare Fig. 2 with 
Suppl. Fig. 2B).
Compromising Hsp90 expression 
compromises survival potential  
of senescent cells
We show that interference with high affinity confor-
mation of Hsp90 with 17AAG32 accelerates doxo-
rubicin induced senescence. In these experiments 
17AAG treatment per se will not affect Hsp90 
expression or its synthesis, but interferes with its 
high affinity  conformation. Therefore, to study 
whether compromised Hsp90 expression will have 
any effect on senescence activation, IMR-32 cells on 
the onset of senescence were transiently transfected 
with siRNA to knockdown Hsp90 (2 µg/0.4 × 106 
cells). After 24 h siRNA treatment, knockdown of 
Hsp90 expression was confirmed by examining the 
hsp90 mRNA levels (Suppl. Fig. 3).  Subsequently, 
cells were tested for SA-β-gal staining and cyto-
toxicity. A significant decrease in SA-β-gal  positive 
cells in day-2, -4 and -6 (Fig. 6C and D, P , 0.05) 
with a concomitant increase in cytotoxicity (Fig. 6E) 
implied that Hsp90 expression is indispensible 
for cell survival. Chronic expression of Hsp90 is 
required for cell survival, but not the high affin-
ity conformation, where the latter is involved in 
oncogenic signal transduction and enhanced cell 
proliferation.32,33
cM-SASPs from senescent cells induce 
senescence
Enforced senescence in tumor cells has also been pro-
posed to be deleterious, because it activates age-as-
sociated pathologies.34 The genotoxic stress enhances 
senescence associated secretory phenotype (SASP), 
which however, is linked to the loss of p53 function 
or enhanced oncogene activation.35 Since, IMR-32 
hsp90 inhibition accelerates senescence
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exhibit functional p53 and chronic oncogene activa-
tion, we examined CM containing SASPs from senes-
cent cells on pro-senescence activity. Between the two 
cell types used in our study, jurkat cells mimic T-cell 
leukemia and secret cytokines, whereas, SRA01 are 
virus free immortalized cells containing progenitors 
of myoepithelial lacking tumorigenic activity. The 
CM treated tumor cells showed senescence morphol-
ogy by 4-day treatment as observed by SA-β-gal 
staining. Interestingly, between jurkat and SRA01, 
the SRA01 showed 50% less SA-β-gal  positive cells, 
however, were associated with enhanced  cytotoxicity. 
These experiments suggested that the paracrine activ-
ities of SASPs in our model lack tumor promoting 
factors but retained senescence activating factors 
(Fig. 7A).
Discussion
Neuroblastoma has been considered as a  malignant 
manifestation of aberrant sympathetic nervous 
system development. Irreconcilable differences in 
therapeutic strategies due to high tumor hetero-
geneity limit existing approaches, thus, insist on 
developing novel strategies, which can exploit the 
oncogenic signatures of tumor cells.36 Earlier, we 
showed that pharmacological targeting of Hsp90 
functions deprives proliferation promoting signal 
transduction in IMR-32 neuroblastoma, however, 
the apparent recurrence on post-treatment sug-
gested limitations to this approach.6,37 In this study, 
we demonstrate how compromising the chaperon-
ing functions of Hsp90 (17AAG pre-treatment) 
sensitizes neuroblastoma to doxorubicin induced 
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cellular senescence, and present conformation spe-
cific Hsp90 as a barrier to enforced senescence of 
tumor cells.
Although Hsp90 is an exciting drug target due to 
its cancer specificity it is likely to induce drug resis-
tance over time.38 Some Hsp90 inhibitors can induce 
oxidative stress leading to non-specific actions in 
tumor cells and may also affect bystander cells.39 
However, in the present study, microgram concen-
trations of 17AAG for prolonged incubation peri-
ods is required to obtain 50% cells death, which 
may develop drug resistance in cancer cells in due 
course of time. Similar findings with doxorubicin 
suggested ability of cells to resist chemotherapeutic 
intervention. Although combination drug treatment 
has improved the cytotoxic effects of drugs in ear-
lier time periods, prolonged periods of incubation 
suggested either delayed drug response or acquired 
drug resistance (Supplemental Fig. 1B). Doxorubicin 
pre-treatment followed by 17AAG did not improve 
efficacy of cytotoxic treatment strategy, but 17AAG-
pretreatment has significantly decreased cytotoxicity 
(Supplemental Fig. 2B). To our surprise, SA-β-gal 
staining indicative of senescence was observed in 
17AAG pre-treatments suggesting bypassing che-
motherapeutics induced cytotoxicity results in cel-
lular senescence. The increase in SA-β-gal positive 
cells was almost doubled in 17AAG pre-sensitization 
compared to doxorubicin treatment alone (compare 
Fig. 1A1 with Fig. 2A1).
In recent years, enforcing premature senes-
cence in tumor cells with chemotherapeutic media-
tion has been proposed as an alternate strategy to 
combat cancers.40,41 Prolonged cytostasis either 
through  p53-p21CIP/WAF-1 or pRb-p16INK4a meditation 
was thought to be the focal point in such models.42 
Despite the fact that individual drug treatments do 
not show significant increase in p21CIP/WAF-1 expres-
sion, the combination treatment showed increased 
p21CIP/WAF-1 expression correlating with p53 (compare 
Fig. 1B and C with Fig. 2D and E) that however, 
did not result in increased senescence positive cells 
(compare Fig. 1A1 with Fig. 2A1). The increased 
p21CIP/WAF-1 expression only in 17AAG pre-treat-
ment but not in doxorubicin pre-treatment resulted 
in increased senescence positive cells (Fig. 2). 
Although, replicative senescence is linked to p16INK4a, 
in our study, incessant p16INK4a over expression was 
found to have no influence on induced senescence 
signaling in individual and combination drug treat-
ments (Fig. 1), but its decrease in 17AAG pre-treat-
ment resulted in significant increase in senescence 
positive cells (Fig. 2). We speculate that p16INK4a 
may be antagonizing senescence signaling induced 
by chemotherapeutic interventions. In accordance 
with this, p16INK4a constitutive expression22 has been 
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Figure 7. (A) conditioned medium induced senescence activity in jurkat 
and SrA01 cells. The conditioned medium from 17AAg pre-treatment 
accelerated senescence cells was examined for pro-senescence activ-
ity in pre-malignant (jurkat) and immortal cells (SrA01) for 6-days and 
cells were stained for SA-β-gal activity. note decreased number of SA-β-
gal positive cells in SrA01 cells compared to jurkat cells. (B) Proposed 
senescence activation model.
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implicated in bypassing cellular senescence.43 We are 
in the process of examining the role of p16INK4a in 
tumor metastasis and bypassing induced senescence. 
Excluding p16INK4a in 17AAG pre-treatment induced 
senescence, the senescence observed in our model is 
pragmatic to p53-p21CIP/WAF-1 mediation.
Interestingly, the stress proteins (Hsp27, Hsp70 
and Hsp90) that showed fluctuations in individual and 
combination drug treatments (Fig. 1) were not signifi-
cantly affected by the followed drug treatments (Fig. 2) 
implicating functional compromise but not expression 
levels play role in altering the cell fate. Consistent with 
this stabilized p53 and p21CIP/WAF-1 levels appeared to 
play significant role in cellular decision correlat-
ing with differentially regulated cdks. In accordance 
with this we did not find complete loss of prolifera-
tion (PI3K-AKT) or survival (Ras-Raf-ERK) signal 
transduction but their apparent alteration (Fig. 1 and 
Fig. 2). The continued kinase activities may therefore 
relate to cellular crisis induced by the combination 
drug treatments. The data obtained from Figures 1 and 
2 however failed to conform to any classical signal 
transduction pathway leading to senescence, it con-
firmed that senescence occurred through p53-p21CIP/
WAF-1 mediation. With this lead we went ahead for fur-
ther characterization of senescence.
Enhanced SAHF is involved in maintaining the 
senescence phenotype. Although SA-β-gal staining 
can be used to detect both cellular stress response 
as well as senescence response, increased SA-β-gal 
staining with increased nucleus to cytoplasm ratio 
indicated the onset of senescence (Supplemental 
Figs. 1A and 2A), which further correlated with a 
time dependent increase in SAHF staining (Fig. 3D). 
Our results may differ with the findings of Restall 
and Lorimer,44 who reported that Hsp90 inhibition 
alone can induce premature senescence in small cell 
lung carcinoma (SCLC). The SAHF increase in their 
study has been correlated to senescence associated 
with DDR response to DNA damage. Studies from 
different groups indicate that Hsp90 inhibition per 
se will not induce DNA damage but compromises 
DDR.45,46 We bring forth evidence from the present 
study that compromising the chaperoning functions 
of Hsp90 with 17AAG enhances the doxorubicin 
induced DDR in neuroblastoma. Another marker of 
senescence, H3K4me3 suggests increased patterns of 
histone acetylation and competence of transcriptional 
 activation47 thus negates SAHFs. However, in the pres-
ent model, H3K4me3 cytoplasmic accumulation has 
invalidated its role in active chromatin transcription. 
Nevertheless, F-actin re-organization and increased 
cell granularity together with non-functional telom-
erases has appraised telomerase-independent senes-
cence activation (Fig. 3).
Physiological factors such as ROS and Ca2+ were 
also implicated in senescence signaling. In fact 
aging phenotypes were thought to be established 
through oxidative signaling. Since Hsp90 inhibi-
tors alone can elevate ROS,39 in the present study, 
the ROS mediated senescence activation48,49 cannot 
be exempted. To our surprise, we observed only a 
small but gradual increase in ROS levels, which were 
addressed by the activated mitochondrial antioxidant 
defense. These findings sets aside the role of ROS in 
senescence activation.27,50,51 Although Hsp90 inhibi-
tion induces the release of intracellular Ca2+,52 in a 
rat tumor model, this release was then correlated to 
decreased functions of Hsps.53 Unlike the rat model 
where Hsp gene transcription was found to be com-
promised, IMR-32 cells retained some Hsps sug-
gesting survival potential of cells upon elevated Ca2+ 
levels.  Reinforcing this, the increased calcium levels 
correlated with the activation of senescence response 
but not apoptosis (Fig. 4). In previous sections we dis-
cussed how senescent cells are resistant to cell death 
mechanisms such as apoptosis under conditions of 
depleted oxygen stress54 and now in agreement with 
this, in the present study, we observed activation of 
autophagy, which was considered to be pro-survival 
response mechanism.
Senescence mediated by p53-p21CIP/WAF-1 has been 
reported to be reversible therefore may limit the appli-
cation of our strategy. Failing to induce senescence 
reversal with mTOR inhibitor, EGF or curcumin that 
were known to decelerates senescence,55,56 appraise 
that enforced proliferation stimulus is inoperative 
once senescence signal is being activated. In accor-
dance with earlier understanding that synergistic acti-
vation of PI3K and mTOR provide survival fitness 
to cancer cells,57 and their chronic activation lead to 
senescence,58 we demonstrated that drug treatments 
promote senescence through chronic signal activa-
tion (Fig. 5). Therefore the irreversible potential 
of tumor cells may relate to enhanced senescence-
 associated multi drug resistance.59 Doxorubicin being 
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the substrate of multi drug resistance gene prod-
uct, MDR1,60 it was presumed that Hsp90 inhibi-
tion promotes its bioavailability to exhibit enhanced 
 senescence  activity. With the prelude that Hsps pro-
mote multidrug resistance in tumor cells, we interpret 
that functional Hsp90 inhibition in MDR1 positive9 
IMR-32 cells could possibly have primarily com-
promised the drug efflux, thus could have increased 
doxorubicin cellular accumulation to promote senes-
cence associated effects.
The augmentation of doxorubicin induced senes-
cence by Hsp90 inhibitors in neuroblastoma suggests 
an alternate strategy to combat cancers. Evaluation 
whether enforced cellular senescence act as a tumor 
suppression mechanism by anchorage indepen-
dent (growth on agarose) and anchorage dependent 
(growth on matrigel) growth assays revealed anti-pro-
liferative and anti-angiogenic competence. However, 
in contrast to compromising of Hsp90 chaperoning 
function using pharmacological drugs, knockdown of 
Hsp90 using siRNA has significantly compromised 
the survival potential of senescent population (Fig. 6) 
suggesting Hsp90 expression is indispensible for cell 
survival whether cells are from normal, tumor or 
senescent groups.
Paradoxically chemotherapeutic drugs must 
exert two important tumor suppressor mechanisms 
namely, senescence or apoptosis. Hsps antagonize 
apoptotic signaling1,53 but facilitates senescence.61 
The conformational maturation and functional sta-
bilization of oncogenes was aided by conformation 
specific Hsp90 (high affinity conformation) present 
in tumor cells, which is in addition to the presence 
of normal Hsp90 (low affinity conformation).32 In 
the present study, pre-sensitization of tumor cells 
with conformation specific anti-Hsp90 inhibitor, 
17AAG to doxorubicin treatment suggested that 
by compromising high affinity conformation of 
Hsp90 it may be possible to sensitize Hsp90 inhi-
bition resistant tumor cells to chemotherapeutic 
intervention. Our results demonstrate that Hsp90 in 
its high affinity conformation undeniably acts as 
an impediment to senescence signaling due to its 
involvement in tumor progression. Our findings are 
in agreement with earlier hypothesis that decreased 
chaperoning functions of Hsps promote senescence 
signaling.62,63
Findings from Campici’s group64 though projected 
enforced cellular senescence as a tumor suppressor 
mechanism, later findings from the same group showed 
that factors secreted to the culture medium (condition 
medium-CM) by  senescent cells (SASPs) can pro-
mote transformation in  pre- malignant cells.34,65 These 
findings invalidated the strategy of enforced cellular 
senescence for antitumor treatment.66 Nevertheless, we 
project that CM from 17AAG pre-treatment induced 
senescent cells lack proliferation stimulus as envi-
sioned by other groups but interestingly accelerated 
senescence-like phenotype in target cells (Fig. 7A). 
The disparity in SASPs from others to our study was 
found to be only the use of Hsp90 inhibition to accel-
erate senescence. Our findings, therefore, may have 
clinical benefits for cutting-edge treatments using 
anti-Hsp90 drugs. For thorough understanding of the 
molecular cross-talk in neuroblastoma, at this point in 
time we are characterizing SASPs and also investigat-
ing the functional silencing of p16INK4a and its contri-
bution in bypassing senescence in IMR-32 cells.
In summary, both cancer and senescence cells 
express high amounts of Hsps, however, differ in 
their chaperoning activities. While enhanced chap-
eroning functions of Hsp90 with increased ATP 
binding affinity promote tumor progression allow-
ing mutated gene products to function normally, the 
basal functions help to maintain protein homeosta-
sis. Taking leads from these findings, we manipu-
lated the chaperone functions of Hsp90 and studied 
genotoxic drug-induced cellular senescence in IMR-
32 neuroblastoma. Among different individual and 
combination drug treatments, pre-sensitization of 
neuroblastoma with 17AAG accelerated doxorubi-
cin induced DDR and signaled cells to stress induced 
cellular senescence. Despite its known functions in 
replicative senescence67,68 we demonstrate how DDR 
signaling promote stress-induced senescence. Several 
cellular factors, signaling molecules and second mes-
sengers that have contributed to enforced senescence 
in IMR-32 neuroblastoma were discussed.  Essentially 
Hsp90 as a barrier for enforced senescence in tumor 
cells was emphasized (Fig. 7B). Our findings add 
contemporary information, attractive strategy and 
effective therapeutic option wherein exploitation of 
conformation specific Hsp90 in sensitizing metastatic 
tumor cells leads to enforced cellular senescence.
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supplementary Figures
Figure s1. Effect of 17AAG, doxorubicin and their combination on cell morphology and cytotoxicity. (A) cells after respective treatments were observed 
under microscope and phase contrast images in 10x magnification were represented. (B) cells were stained with propidium iodide and the DnA content 
was analyzed by FAcS.
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Figure s2. Effect of drugs pre-treatments on cell morphology and cytotoxicity. (A) Cells either treated with doxorubicin or 17AAG for 24 h followed by 
second drug treatment for 5-days were observed under microscope and the phase contrast images were represented. (B) cells stained with propidium 
iodide and the DnA content was analyzed by FAcS.
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Figure s3. The rT-Pcr analysis of sirnA to hsp90 transfected cells.
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